Final height in central precocious puberty after long term treatment with a slow release GnRH agonist

Archives of Disease in Childhood

Volumn 75, Issue 4, 1996, Pages 292-297

  Oostdijk, Wilma ^a,i   Rikken, Berthon ^a   Schreuder, Sandra ^a   Otten, Barto ^b   Odink, Roelof ^c   Rouwé, Cathrinus ^d   Jansen, Maarten ^e   Gerver, Willem Jan ^f   Waelkens, Johan ^g   Drop, Stenvert ^h  

^a LEIDEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

^h ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Central precocious puberty; Final height; GnRH agonist

Indexed keywords

BUSERELIN; CYPROTERONE ACETATE; GONADORELIN AGONIST; TRIPTORELIN;

ARTICLE; BODY HEIGHT; BONE MATURATION; CHILD; CLINICAL ARTICLE; DEVELOPMENT; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL;

EID: 10244222267     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.75.4.292     Document Type: Article

References (32)

1. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7:24-33.
2. Comite F, Cassorla F, Barnes KM, et al. LHRH analogue therapy for central precocious puberty. JAMA 1986;255: 2613-6.
3. Drop SLS, Odink RJH, Rouwé C, et al. The effect of treatment with an LHRH agonist (Buserelin) on gonadal activity, growth and bone maturation in children with central precocious puberty. Eur J Pediatr 1987;146:272-8.
4. Bourguignon JP, Van Vliet G, Vandeweghe M, et al. Treatment of central precocious puberty with an intranasal analogue of GnRH (Buserelin). Eur J Pediatr 1987;146: 555-60.
5. Stanhope R, Pringle PJ, Brook CGD. Growth, growth hormone and sex steroid secretion in girls with central precocious puberty treated with a gonadotrophin-releasing hormone (GnRH) analogue. Acta Pediatr Scand 1988;77: 525-30.
6. Lee PA, Page JG, and the leuprolide study group. Effects of leuprolide in the treatment of central precocious puberty. J Pediatr 1989;114:321-4.
7. Oostdijk W, Hummelink R, Odink RJH, et al. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist. Eur J Pediatr 1990;149:308-13.
8. Kreiter M, Burstein S, Rosenfield RL, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990;117:364-70.
9. Stanhope R, Preece MA, Grant DB, Brook CGD. New concepts of the growth spurt of puberty. Acta Paediatr Scand 1988;347(suppl):30-7.
10. Kauli R, Kornreich L, Laron Z. Pubertal development, growth and final heights in girls with sexual precocity after therapy with the GnRH agonist D-Trp-6-LHRH. Horm Res 1990;33:11-7.
11. Boepple PA, Mansfield MJ, Crawford JD, Crigler JF, Blizzard RM, Crowley WF. Final height in girls with central precocious puberty following GnRH-agonist induced pituitary-gonadal suppression. Pediatr Res 1991;29:74A.
12. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab 1991;73: 1235-40.
13. Brauner R, Adan L, Malandry F, Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994;79:415-20.
14. Manasco PK, Pescovitz OH, Feuillan PP, et al. Resumption of puberty after longterm luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988;57:368-72.
15. Chaussain JL, Swaenepoel C, Bost M, et al. Growth and ovary function in girls with central precocious puberty after interruption of GnRH analogue therapy. Horm Res 1990;33(suppl 3):5A.
16. Jay N, Mansfield J, Blizzard RM, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75:890-4.
17. Adams JM, Boepple PA, Crowley WF. The use of ultrasound in the evaluation of central precocious puberty. In: Grave GD, Cutler GB, eds. Sexual precocity. New York: Raven Press, 1993:166-79.
18. Partsch CJ, Hummelink R, Peter M, et al. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty. Harm Res 1993;39:111-7.
19. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long term effect of gonadotropinreleasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546-51.
20. Oostdijk W, Partsch CJ, Drop SLS, Sippell WG. Hormonal evaluation during and after longterm treatment with a slow-release GnRH-agonist of children with central precocious puberty. In: Plant TM, Lee PA, eds. The neurobiology of puberty. Bristol: Journal of Endocrinology Ltd, 1995: 319-25.
21. Rolland-Cachera MF, Deheeger M, Bellisle F, Sempe M, Guilloud-Bataille M, Patois E. Adiposity indices in children. Am J Clin Nutr 1982;36:178-84.
22. Roede MJ, van Wieringen JC. Growth diagrams 1980. Netherlands third nation-wide biometric survey. T Soc Gezondheidsz 1985:63(suppl):1-34.
23. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children from birth to 20 years of age: first Zürich longitudinal study of growth and development. Helv Paediatr Acta 1989;43(suppl 52):5-6.
24. Greulich W, Pyle SL. Radiographic atlas of skeletal development of the hand and wrist. 2nd Ed. Stanford: Stanford University Press, 1966.
25. Haber HP, Mayer EI. Ultrasound evaluation of uterine and overian size from birth to puberty. Pediatr Radiol 1994;24: 11-13.
26. Thamdrup E. Precocious sexual development. A clinical study of 100 children. Springfield: Thomas, 1961.
27. Sigurjonsdottir IJ, Hayles AB. Precocious puberty: a report of 96 cases. Am J Dis Child 1968;115:309-21.
28. Bourguignon JP. Linear growth as a function of age at onset of puberty and sex steroid dosage: therapeutic implications. Endocr Rev 1988;9:467-88.
29. Mueller WH. The genetics of size and shape in children and adults. In: Falkner F, Tanner JM, eds. Human growth. New York: Plenum 1986:145-68.
30. Neyzi O, Darendeliler F. Growth hormone treatment in syndromes with short statue, including Down syndrome, Prader-Labhardt-Willi syndrome, von Recklinghausen syndrome, Williams syndrome and others. In: Ranke MB, Gunnarsson R, eds. Progress in growth hormone therapy - 5 years of KIGS. Mannheim: J&J Verlag, 1994:240-55.
31. Marti-Henneberg C, Moreno A, Sanchis F, Fernandez-Ballart J. Tempo of puberty and final height in girls. Horm Res 1994;41(suppl):102.
32. Jay N, Mansfield MJ, Blizzard RM, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992; 75:890-4.